Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase

Rilpivirine in combination with background ART was well-tolerated and maintained virologic suppression from baseline through week 48 in the studied population of children living with HIV-1. Rilpivirine exposure was within the target range for all doses.

Authors

Institutions

Publication Details

Journal
The Pediatric Infectious Disease Journal
Published
2025-08-13
DOI
https://doi.org/10.1097/inf.0000000000004943
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase

Simon Vanveggel, Francis Ssali, Minaka Shibuya, Ken Kurosawa et al.
The Pediatric Infectious Disease Journal
Cannabis and Cannabinoid Research
article

Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase

Simon Vanveggel, Francis Ssali, Minaka Shibuya, Ken Kurosawa, Johan Lombaard, Sandy Van Hemelryck, Clàudia Fortuny, Supattra Rungmaitree, Erika Van Landuyt, Rodica Van Solingen‐Ristea, Alberto Russu, Margarida Tavares, Veerle Van Eygen, Visal Moolasart, Raffaele Badolato, Alfredo Guarino, Stefania Bernardi, Linda Aurpibul
article en

Abstract

Rilpivirine in combination with background ART was well-tolerated and maintained virologic suppression from baseline through week 48 in the studied population of children living with HIV-1. Rilpivirine exposure was within the target range for all doses.

The Pediatric Infectious Disease JournalVol. 44(11)
Hospital Sant Joan de Déu Barcelona (ES), Ministry of Public Health (TH), Siriraj Hospital (TH), Mahidol University (TH), Hospital de São João (PT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Johnson Controls (Japan) (JP), Bamrasnaradura Infectious Diseases Institute (TH), Federico II University Hospital (IT), Bambino Gesù Children's Hospital (IT), Johnson & Johnson (Italy) (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Joint Clinical Research Centre (UG), University of Brescia (IT)
Janssen Research and Development
Good health and well-being
Openalex Percentile: Top 76%
Cannabis and Cannabinoid Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.